Heska Revenue Growth Rates (HSKA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Heska Corporation  (NASDAQ: HSKA)
 

HSKA's Revenue Growth by Quarter and Year

Heska's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HSKA Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 62.38
FY 62.38

HSKAs Annual Revenue
Heska's Revenue in the fiscal year 2022 $ 257.31 millions
Heska's Revenue in the fiscal year 2021 $ 253.74 millions
Heska's Revenue in the fiscal year 2020 $ 197.32 millions
Heska's Revenue in the fiscal year 2019 $ 122.66 millions
Heska's Revenue in the fiscal year 2018 $ 127.45 millions




HSKA Revenue first quarter 2023 Y/Y Growth Comment
Heska Corporation reported decrease in Revenue in the first quarter 2023 by -3.73% to $ 62.38 millions, from the same quarter in 2022.
The decrease in the first quarter 2023 Heska Corporation's Revenue compares unfavorably to the Company's average Revenue increase of 14.48%.

Looking into first quarter 2023 results within In Vitro & In Vivo Diagnostic Substances industry 9 other companies have achieved higher Revenue growth. While Heska Corporation' s Revenue decline of -3.73% ranks overall at the positon no. 2831 in the first quarter 2023.


HSKA Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - -2.54 % 5.83 % 90.46 %
3rd Quarter September - 2.08 % 6.36 % 81.31 %
2nd Quarter June - -0.39 % 42.05 % 62.38 %
1st Quarter March -3.73 % 7.11 % 97.39 % 3.86 %
FY   - 1.41 % 28.59 % -

Financial Statements
Heska's first quarter 2023 Revenue $ 62.38 millions HSKA's Income Statement
Heska's first quarter 2022 Revenue $ 64.80 millions Quarterly HSKA's Income Statement


HSKA Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 7.89 % 13 % 13.56 %
3rd Quarter September - -4.93 % -7.22 % 23.91 %
2nd Quarter June - -0.19 % 7.32 % 49.14 %
1st Quarter March -5.97 % -4.8 % -5.94 % -9.24 %
FY (Year on Year)   - 1.41 % 28.59 % -


Back to HSKA Growth rate Comparisons >> Back to HSKA Growth rate Comparisons >>


Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #10
Healthcare Sector #454
Overall #2831

Revenue Y/Y Growth Statistics
High Average Low
133.35 % 14.48 % -16.05 %
(Dec 31 2020)   (Dec 31 2017)
Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #10
Healthcare Sector #454
Overall #2831
Revenue Y/Y Growth Statistics
High Average Low
133.35 % 14.48 % -16.05 %
(Dec 31 2020)   (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Heska's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
49.12 % 1.95 % -100 %
(Jun 30 2020)  


HSKA's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Heska Corporation disclosed decline in Revenue from the fourth quarter by -5.97% to $ 62.38 millions, from $ 66.34 millions achived in the previous reporting period.

But that's not important problem, as Heska's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Heska's Revenue growth quarter on quarter, overall rank is 2749.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #10
Healthcare Sector #431
Overall #2749
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #10
Healthcare Sector #431
Overall #2749
Revenue Q/Q Growth Statistics
High Average Low
49.12 % 1.95 % -100 %
(Jun 30 2020)  


HSKA's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Heska Corporation disclosed decline in Revenue from the fourth quarter by -5.97% to $ 62.38 millions, from $ 66.34 millions achived in the previous reporting period.

But that's not important problem, as Heska's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Heska's Revenue growth quarter on quarter, overall rank is 2749.


Heska's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 254.89 $ 257.31 $ 259.04 $ 257.79 $ 258.04
Y / Y Revenue Growth (TTM) -1.22 % 1.41 % 3.62 % 4.63 % 13.59 %
Year on Year Revenue Growth Overall Ranking # 1491 # 646 # 1650 # 2146 # 1764
Seqeuential Revenue Change (TTM) -0.94 % -0.67 % 0.49 % -0.1 % 1.69 %
Seq. Revenue Growth (TTM) Overall Ranking # 2538 # 2243 # 1507 # 2857 # 2130


Cumulative Revenue growth Comment
For the 12 months ended Mar 31 2023 Heska reported a decrease in Revenue by -1.22% year on year, to $255 millions, compare to the 1.41% growth at Dec 31 2022.

In the Healthcare sector 237 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 646 to 1491.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 238
Overall # 1491

Revenue TTM Y/Y Growth Statistics
High Average Low
110.71 %
 17.36 %
-7.73 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 357
S&P 500 # 2538
Cumulative Revenue growth Comment
For the 12 months ended Mar 31 2023 Heska reported a decrease in Revenue by -1.22% year on year, to $255 millions, compare to the 1.41% growth at Dec 31 2022.

In the Healthcare sector 237 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 646 to 1491.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 238
Overall # 1491

Revenue TTM Y/Y Growth Statistics
High Average Low
110.71 %
17.36 %
-7.73 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 357
S&P 500 # 2538




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HSKA's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Regenerx Biopharmaceuticals inc -0.01%$ -0.005 millions
Community Health Systems Inc -0.10%$ -0.096 millions
West Pharmaceutical Services Inc -0.47%$ -0.472 millions
Butterfly Network Inc -0.63%$ -0.629 millions
Qhslab Inc -0.71%$ -0.712 millions
Waters Corporation-0.85%$ -0.854 millions
Dariohealth Corp -0.86%$ -0.856 millions
Fresenius Medical Care Ag-1.06%$ -1.058 millions
Acorda Therapeutics Inc -1.22%$ -1.225 millions
Baxter International Inc -1.56%$ -1.565 millions
Kymera Therapeutics Inc -1.62%$ -1.621 millions
Nature s Sunshine Products inc -1.68%$ -1.683 millions
Organon and Co -1.85%$ -1.851 millions
Scientific Industries Inc -2.08%$ -2.077 millions
Amgen Inc -2.13%$ -2.132 millions
Healthcare Services Group Inc -2.24%$ -2.245 millions
Adaptive Biotechnologies Corporation-2.52%$ -2.519 millions
Bristol myers Squibb Company-2.67%$ -2.670 millions
Caredx Inc -2.71%$ -2.712 millions
Biogen Inc -2.72%$ -2.717 millions
Innovage Holding Corp -2.72%$ -2.718 millions
Cardiff Lexington Corporation-2.73%$ -2.727 millions
Apyx Medical Corp-2.81%$ -2.810 millions
Avanos Medical Inc -2.89%$ -2.888 millions
Align Technology inc -3.09%$ -3.090 millions
Bio rad Laboratories Inc -3.32%$ -3.317 millions
Enhabit Inc -3.35%$ -3.354 millions
National Healthcare Corp-3.38%$ -3.377 millions
Thermogenesis Holdings Inc -3.42%$ -3.417 millions
Mesoblast Limited-3.58%$ -3.580 millions


About Heska Revenue Growth Rates (HSKA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Heska Corp (CIK 1038133).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001038133-23-000023
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Heska Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.